CY1109356T1 - Θειολακτονες ως αναστολεις της νααladασης - Google Patents
Θειολακτονες ως αναστολεις της νααladασηςInfo
- Publication number
- CY1109356T1 CY1109356T1 CY20091100904T CY091100904T CY1109356T1 CY 1109356 T1 CY1109356 T1 CY 1109356T1 CY 20091100904 T CY20091100904 T CY 20091100904T CY 091100904 T CY091100904 T CY 091100904T CY 1109356 T1 CY1109356 T1 CY 1109356T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- activity
- thiolakes
- naladasis
- analysis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 abstract 2
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000017497 prostate disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45064803P | 2003-03-03 | 2003-03-03 | |
| EP04716834A EP1599461B1 (en) | 2003-03-03 | 2004-03-03 | THIOLACTONES AS NAALADase INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109356T1 true CY1109356T1 (el) | 2014-07-02 |
Family
ID=32962505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100904T CY1109356T1 (el) | 2003-03-03 | 2009-08-28 | Θειολακτονες ως αναστολεις της νααladασης |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7125907B2 (enExample) |
| EP (2) | EP1599461B1 (enExample) |
| JP (1) | JP4773951B2 (enExample) |
| AT (1) | ATE433445T1 (enExample) |
| AU (1) | AU2004217969B2 (enExample) |
| CA (1) | CA2518234C (enExample) |
| CY (1) | CY1109356T1 (enExample) |
| DE (1) | DE602004021476D1 (enExample) |
| DK (1) | DK1599461T3 (enExample) |
| ES (1) | ES2326083T3 (enExample) |
| MX (1) | MXPA05009492A (enExample) |
| PL (1) | PL1599461T3 (enExample) |
| PT (1) | PT1599461E (enExample) |
| SI (1) | SI1599461T1 (enExample) |
| WO (1) | WO2004078742A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004217969B2 (en) * | 2003-03-03 | 2011-03-03 | Eisai Inc. | Thiolactones |
| EP2120555A1 (en) * | 2007-01-31 | 2009-11-25 | Adam Heller | Methods and compositions for the treatment of pain |
| EP3337520A1 (en) * | 2015-08-20 | 2018-06-27 | Universität zu Köln | Pain tracking by pet-imaging (pain-trap) |
| EP4097119B1 (en) * | 2020-01-31 | 2025-05-07 | The Johns Hopkins University | Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239636A (en) * | 1978-10-23 | 1980-12-16 | Exxon Research & Engineering Co. | Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions |
| JPH0532659A (ja) * | 1991-08-01 | 1993-02-09 | Tsumura & Co | 糖尿病治療剤 |
| GB9218810D0 (en) * | 1992-09-04 | 1992-10-21 | Univ Birmingham | Antiviral pyrimidine nucleosides |
| US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| GB9602721D0 (en) | 1996-02-09 | 1996-04-10 | Pharmacia Spa | Biologically active ureido derivatives useful in the treatment of multiple sclerosis |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US5977090A (en) * | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| IL127605A0 (en) * | 1996-06-17 | 1999-10-28 | Guilford Pharm Inc | Methods of cancer treatment using naaladase inhibitors |
| US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| GB9615202D0 (en) | 1996-07-19 | 1996-09-04 | Smithkline Beecham Plc | Pharmaceuticals |
| CZ60499A3 (cs) * | 1996-09-27 | 1999-08-11 | Guilford Pharmaceuticals Inc. | Prostředky s účinkem na NAALADázy, způsoby léčení glutamátové abnormality a způsoby ovlivňování neuronální aktivity u živočichů |
| US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| US6265609B1 (en) * | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| TR200100025T2 (tr) * | 1998-07-06 | 2001-12-21 | Guilford Pharmaceuticals Inc. | Farmasötik bileşikler ve kompozisyonlar olarak faydalı naaladaz inhibitörleri. |
| US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| CA2367787C (en) * | 1999-04-28 | 2011-07-26 | Alan P. Kozikowski | Ligands for metabotropic glutamate receptors |
| US6228888B1 (en) | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| US6313159B1 (en) * | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
| US6348464B1 (en) * | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
| AU2001265111A1 (en) * | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| AU2001265119A1 (en) | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| JP2003535098A (ja) * | 2000-05-30 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレーティッド | 網膜疾患および緑内障を治療するためのｎａａｌａｄアーゼ阻害剤 |
| WO2002052949A1 (en) * | 2001-01-08 | 2002-07-11 | Gormar Marketing Limited | Autoinducer compounds and their uses |
| FR2819253B1 (fr) * | 2001-01-11 | 2004-12-03 | Servier Lab | Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1353903A2 (en) | 2001-01-17 | 2003-10-22 | Guilford Pharmaceuticals Inc. | Thiol-based naaladase inhibitors |
| US6884907B2 (en) * | 2001-05-11 | 2005-04-26 | Guilford Pharmaceuticals Inc. | Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
| MXPA03010859A (es) * | 2001-05-30 | 2004-02-17 | Guilford Pharm Inc | Derivados de acido tioalquilbenzoico. |
| US20050080139A1 (en) | 2001-12-28 | 2005-04-14 | Slusher Barbara S. | Naaladase inhibitors for treating huntington's disease |
| US20040186081A1 (en) * | 2003-03-03 | 2004-09-23 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating opioid tolerance |
| AU2004217969B2 (en) | 2003-03-03 | 2011-03-03 | Eisai Inc. | Thiolactones |
-
2004
- 2004-03-03 AU AU2004217969A patent/AU2004217969B2/en not_active Ceased
- 2004-03-03 DE DE602004021476T patent/DE602004021476D1/de not_active Expired - Lifetime
- 2004-03-03 AT AT04716834T patent/ATE433445T1/de active
- 2004-03-03 EP EP04716834A patent/EP1599461B1/en not_active Expired - Lifetime
- 2004-03-03 DK DK04716834T patent/DK1599461T3/da active
- 2004-03-03 WO PCT/US2004/006178 patent/WO2004078742A1/en not_active Ceased
- 2004-03-03 CA CA2518234A patent/CA2518234C/en not_active Expired - Fee Related
- 2004-03-03 PL PL04716834T patent/PL1599461T3/pl unknown
- 2004-03-03 ES ES04716834T patent/ES2326083T3/es not_active Expired - Lifetime
- 2004-03-03 EP EP08013761A patent/EP1988088A1/en not_active Withdrawn
- 2004-03-03 SI SI200431195T patent/SI1599461T1/sl unknown
- 2004-03-03 PT PT04716834T patent/PT1599461E/pt unknown
- 2004-03-03 MX MXPA05009492A patent/MXPA05009492A/es active IP Right Grant
- 2004-03-03 JP JP2006508945A patent/JP4773951B2/ja not_active Expired - Fee Related
- 2004-03-03 US US10/791,278 patent/US7125907B2/en not_active Expired - Fee Related
-
2006
- 2006-10-02 US US11/537,979 patent/US20070037798A1/en not_active Abandoned
-
2007
- 2007-07-30 US US11/830,737 patent/US7553866B2/en not_active Expired - Fee Related
-
2009
- 2009-05-26 US US12/472,251 patent/US7968593B2/en not_active Expired - Fee Related
- 2009-08-28 CY CY20091100904T patent/CY1109356T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004217969B2 (en) | 2011-03-03 |
| CA2518234C (en) | 2012-11-13 |
| PT1599461E (pt) | 2009-07-20 |
| WO2004078742A1 (en) | 2004-09-16 |
| US7125907B2 (en) | 2006-10-24 |
| ATE433445T1 (de) | 2009-06-15 |
| US20070037798A1 (en) | 2007-02-15 |
| PL1599461T3 (pl) | 2009-10-30 |
| US20050004203A1 (en) | 2005-01-06 |
| CA2518234A1 (en) | 2004-09-16 |
| EP1988088A1 (en) | 2008-11-05 |
| DE602004021476D1 (de) | 2009-07-23 |
| DK1599461T3 (da) | 2009-08-17 |
| MXPA05009492A (es) | 2005-12-14 |
| US20100048667A1 (en) | 2010-02-25 |
| US20080004334A1 (en) | 2008-01-03 |
| US7553866B2 (en) | 2009-06-30 |
| US7968593B2 (en) | 2011-06-28 |
| SI1599461T1 (sl) | 2009-10-31 |
| ES2326083T3 (es) | 2009-09-30 |
| JP2006519858A (ja) | 2006-08-31 |
| AU2004217969A1 (en) | 2004-09-16 |
| EP1599461B1 (en) | 2009-06-10 |
| JP4773951B2 (ja) | 2011-09-14 |
| EP1599461A1 (en) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kätzel et al. | Chemical–genetic attenuation of focal neocortical seizures | |
| WO2003057670A3 (en) | Indoles as naaladase inhibitors | |
| WO2002057222A3 (en) | Thiol-based naaladase inhibitors | |
| WO2001092273A3 (en) | Benzenedicarboxylic acid derivatives | |
| CY1108893T1 (el) | Παραγωγα θειοαλκυλ βενζοϊκου οξεος | |
| WO2005025511A3 (en) | Potassium channel mediated delivery of agents through the blood-brain barrier | |
| BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
| TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
| Maheshwari et al. | Shift in interictal relative gamma power as a novel biomarker for drug response in two mouse models of absence epilepsy | |
| WO2003103585A3 (en) | Methods of treating angiogenesis, tumor growth, and metastasis | |
| CY1109356T1 (el) | Θειολακτονες ως αναστολεις της νααladασης | |
| DE69927502D1 (de) | Naaladase-hemmer anwendbar als pharmazeutische verbindungen und zusammensetzungen | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| MXPA03010328A (es) | Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa. | |
| ATE503474T1 (de) | Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis | |
| DE60037126D1 (de) | POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE | |
| WO2003070883A3 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
| DE602004027255D1 (de) | Peptidische Verbindungen und deren Ableitungen für die Behandllung von menschlichen Krankheiten durch Hemmung der Signalübertragung über Wachstumfaktoren | |
| BRPI0408238A (pt) | anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer | |
| WO2005000406A3 (en) | Treatment of amyloid- and epileptogenesis-associated diseases | |
| WO2002086084A3 (en) | Sequence characteristics of bladder cancer | |
| ATE404677T1 (de) | Behandlungsverfahren unter verwendung von 17906 und dessen anwendungen | |
| WO2003053364A3 (en) | Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 | |
| WO2003039342A3 (en) | Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 | |
| WO2003045229A3 (en) | Methods and compositions for treating cancer |